While soy typically takes up cholesterol research in the legume family, researchers at Tulane University and Arizona State University devised a meta-analysis evaluating non-soy legume consumption and any effect those foods may have had blood lipids.
A meta-analysis in the February 2011 issue of Nutrition, Metabolism, and Cardiovascular Diseases reinforces the potential for non-soy legumes and cholesterol management.
While soy typically takes up cholesterol research in the legume family, researchers at Tulane University (New Orleans) and Arizona State University devised a meta-analysis of randomized controlled trials evaluating non-soy legume consumption and any effect those foods may have had blood lipids.
Using MEDLINE and the Cochrane Collaboration’s Central Register of Controlled Clinical Trials, the researchers gathered 10 randomized clinical trials evaluating non-soy legume diet versus control for a minimum three week’s duration with reported blood lipid changes.
With data from a combined 268 participants in the trials, the research team determined that, compared to placebo, legume diets provided significant reductions of total and low-density lipoprotein (LDL) cholesterol. Total cholesterol was reduced by an average 11.6 mg/dL and LDL cholesterol (commonly known as “bad” cholesterol) was reduced by an average 8 mg/dL.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.